2- (4- acetoxyphenyl)- 2- chloro- N- methylethylamine

a non-steroidal dissociated glucocorticoid receptor (GR) ligand and NSAID; structure in first source

Also Known As:

2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride; 2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride; 2-(acetoxyphenyl)-2-chloro-N-methylethylammonium chloride; 2-APCM-ethylammonium chloride; APCl-MEA chloride; compound A (CpdA)

Networked: 17 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Haegeman, Guy: 5 articles (01/2020 - 11/2009)
2.	De Bosscher, Karolien: 3 articles (01/2018 - 11/2009)
3.	Ide, Hiroki: 2 articles (01/2020 - 10/2015)
4.	Inoue, Satoshi: 2 articles (01/2020 - 10/2015)
5.	Junking, Mutita: 2 articles (01/2020 - 12/2015)
6.	Kashiwagi, Eiji: 2 articles (01/2020 - 10/2015)
7.	Miyamoto, Hiroshi: 2 articles (01/2020 - 10/2015)
8.	Panya, Aussara: 2 articles (01/2020 - 12/2015)
9.	Rattanaburee, Thidarath: 2 articles (01/2020 - 12/2015)
10.	Yenchitsomanus, Pa-Thai: 2 articles (01/2020 - 01/2018)

Related Diseases

1.	Inflammation (Inflammations) 10/01/2013 - "Compound A (CpdA) is a selective GC receptor modulator with an improved risk/benefit profile in mouse models of inflammation and bone loss. " 06/01/2013 - "In the present study, we have employed a TPA-induced model of skin inflammation and epidermal hyperplasia to determine whether partial activation of the glucocorticoid receptor by compound A (CpdA) is sufficient to reverse the effect of TPA treatment. " 01/01/2018 - "Compound A (CpdA), identified as a selective NR3C1/glucocorticoid receptor (nuclear receptor subfamily 3, group C, member 1) modulator, exhibits an inflammation-suppressive effect, largely in the absence of detrimental side effects. " 11/12/2022 - "We previously described that the small drug Compound A (CpdA), a selective glucocorticoid receptor (GR/NR3C1, nuclear receptor subfamily 3, group C, member 1) ligand with demonstrated inflammation-suppressive activity in vivo, is an effective modulator of effector T and dendritic cells and of macrophages, yet, in a GR-independent manner. " 06/01/2015 - "Compound A (CpdA), a selective glucocorticoid receptor agonist, reduces inflammation in murine arthritis models and does not induce diabetes or osteoporosis, thus offering an improved risk:benefit ratio in comparison with glucocorticoids. "
2.	Osteoporosis 06/01/2015 - "Compound A (CpdA), a selective glucocorticoid receptor agonist, reduces inflammation in murine arthritis models and does not induce diabetes or osteoporosis, thus offering an improved risk:benefit ratio in comparison with glucocorticoids. "
3.	Arthritis (Polyarthritis) 06/01/2015 - "Compound A (CpdA), a selective glucocorticoid receptor agonist, reduces inflammation in murine arthritis models and does not induce diabetes or osteoporosis, thus offering an improved risk:benefit ratio in comparison with glucocorticoids. "
4.	Melanoma (Melanoma, Malignant) 01/01/2018 - "This study aims to explore the effect of TLR4 in PTX resistance in triple-negative BCA and advanced melanoma and the effect of compound A (CpdA) to attenuate this resistance. "
5.	Hyperplasia 06/01/2013 - "In the present study, we have employed a TPA-induced model of skin inflammation and epidermal hyperplasia to determine whether partial activation of the glucocorticoid receptor by compound A (CpdA) is sufficient to reverse the effect of TPA treatment. "

Related Drugs and Biologics

1.	Glucocorticoid Receptors (Glucocorticoid Receptor)
2.	Glucocorticoids
3.	2- (4- acetoxyphenyl)- 2- chloro- N- methylethylamine
4.	Chemokines
5.	Cytokines
6.	Ribavirin (Virazole)
7.	Antiviral Agents (Antivirals)
8.	Ligands
9.	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)
10.	NF-kappa B (NF-kB)

Related Therapies and Procedures

1.	Therapeutics